A Phase 1 Study of ABBV-525 in People With B-Cell Lymphoma


Full Title

Study M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies


In this study, researchers want to find the highest dose of the drug ABBV-525 to safely treat B-cell non-Hodgkin lymphoma (NHL). People in this study have B-cell NHL that keeps growing even after standard treatment.

ABBV-525 works by blocking a protein called MALT1. This protein can help B-cell cancers live and grow. Blocking MALT1 may kill cancer cells or stop them from growing. ABBV-525 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have B-cell NHL that keeps growing even after treatment.
  • Have finished all other therapies at least 4 weeks before you get ABBV-525.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 and older.


For more information and to see if you can join this study, please contact Dr. Meghan Thompson’s office at 646-608-4253.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID